603882 金域医学
已收盘 10-23 15:00:00
资讯
新帖
简况
金域医学(603882)10月20日主力资金净买入3999.56万元
证券之星 · 10-21 08:16
金域医学(603882)10月20日主力资金净买入3999.56万元
金域医学涨7.98%,国金证券一个月前给出“买入”评级
证券之星 · 10-20
金域医学涨7.98%,国金证券一个月前给出“买入”评级
金域医学(603882)披露持股5%以上股东权益变动触及1%刻度的提示性公告,10月19日股价上涨2.1%
证券之星 · 10-19
金域医学(603882)披露持股5%以上股东权益变动触及1%刻度的提示性公告,10月19日股价上涨2.1%
金域医学(603882)10月16日主力资金净卖出2152.66万元
证券之星 · 10-17
金域医学(603882)10月16日主力资金净卖出2152.66万元
金域医学(603882)10月15日主力资金净买入1396.44万元
证券之星 · 10-16
金域医学(603882)10月15日主力资金净买入1396.44万元
股市必读:金域医学新发布《广州金域医学检验集团股份有限公司关于终止对外投资的公告》
证券之星 · 10-14
股市必读:金域医学新发布《广州金域医学检验集团股份有限公司关于终止对外投资的公告》
金域医学(603882)披露关于终止对外投资的公告,10月12日股价上涨2.01%
证券之星 · 10-12
金域医学(603882)披露关于终止对外投资的公告,10月12日股价上涨2.01%
股市必读:金域医学新发布《广州金域医学检验集团股份有限公司关于股份回购实施结果暨股份变动的公告》
证券之星 · 10-08
股市必读:金域医学新发布《广州金域医学检验集团股份有限公司关于股份回购实施结果暨股份变动的公告》
金域医学(603882)披露股份回购实施结果暨股份变动公告,9月30日股价上涨2.87%
证券之星 · 09-30
金域医学(603882)披露股份回购实施结果暨股份变动公告,9月30日股价上涨2.87%
股市必读:金域医学(603882)9月24日董秘有最新回复
证券之星 · 09-28
股市必读:金域医学(603882)9月24日董秘有最新回复
金域医学:感染探针捕获、肿瘤多基因检测、全外显子检测等同比分别实现10%~40%增长
证券之星 · 09-24
金域医学:感染探针捕获、肿瘤多基因检测、全外显子检测等同比分别实现10%~40%增长
金域医学:2026年半年度实验室综合人效同比提升15.9%
证券之星 · 09-24
金域医学:2026年半年度实验室综合人效同比提升15.9%
金域医学涨6.06%,国金证券二周前给出“买入”评级
证券之星 · 09-14
金域医学涨6.06%,国金证券二周前给出“买入”评级
每周股票复盘:金域医学(603882)将召开2026年半年度业绩说明会
证券之星 · 09-13
每周股票复盘:金域医学(603882)将召开2026年半年度业绩说明会
金域医学获得发明专利授权:“基因突变分析、查询序列建立方法、系统、设备及介质”
证券之星 · 09-11
金域医学获得发明专利授权:“基因突变分析、查询序列建立方法、系统、设备及介质”
金域医学(603882)披露将召开2026年半年度业绩说明会,9月9日股价上涨0.49%
证券之星 · 09-09
金域医学(603882)披露将召开2026年半年度业绩说明会,9月9日股价上涨0.49%
金域医学新注册《区域检验质控系统V1.0》等2个项目的软件著作权
证券之星 · 09-08
金域医学新注册《区域检验质控系统V1.0》等2个项目的软件著作权
每周股票复盘:金域医学(603882)股东拟减持不超1%股份
证券之星 · 09-06
每周股票复盘:金域医学(603882)股东拟减持不超1%股份
金域医学新注册《金域学术资源运营看板系统APPV1.0》项目的软件著作权
证券之星 · 09-05
金域医学新注册《金域学术资源运营看板系统APPV1.0》项目的软件著作权
股市必读:金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》
证券之星 · 09-03
股市必读:金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》
加载更多
公司概况
公司名称:
广州金域医学检验集团股份有限公司
所属行业:
卫生
上市日期:
2017-09-08
主营业务:
广州金域医学检验集团股份有限公司的主营业务是第三方医学检验及病理诊断业务。公司的主要产品是医学诊断服务、销售诊断产品、健康体检业务、冷链物流服务。公司成功入选国家工业和信息化部公布的第七批产业技术基础公共服务平台名单,成为本次获批单位中唯一一家第三方医检机构,标志着公司的综合实力获得国家权威认可。
发行价格:
6.93
{"stockData":{"symbol":"603882","market":"SH","secType":"STK","nameCN":"金域医学","latestPrice":30.6,"timestamp":1792738800000,"preClose":30.12,"halted":0,"volume":15801800,"delay":0,"changeRate":0.0159,"floatShares":458000000,"shares":463000000,"eps":0.2197,"marketStatus":"已收盘","change":0.48,"latestTime":"10-23 15:00:00","open":29.47,"high":30.75,"low":28.81,"amount":469000000,"amplitude":0.0644,"askPrice":30.6,"askSize":87,"bidPrice":30.59,"bidSize":28,"shortable":0,"etf":0,"ttmEps":0.2197,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":5,"adr":0,"adjPreClose":30.12,"symbolType":"stock","openAndCloseTimeList":[[1792719000000,1792726200000],[1792731600000,1792738800000]],"highLimit":33.13,"lowLimit":27.11,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":463258275,"isCdr":false,"pbRate":2.25,"roa":"--","peRate":139.280838,"roe":"2.92%","epsLYR":-0.37,"committee":0.351609,"marketValue":14176000000,"turnoverRate":0.0345,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-10-26。","floatMarketCap":14016000000},"requestUrl":"/m/hq/s/603882/","defaultTab":"news","newsList":[{"id":"2677610960","title":"金域医学(603882)10月20日主力资金净买入3999.56万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677610960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677610960?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:16","pubTimestamp":1792541776,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月20日收盘,金域医学报收于31.53元,上涨7.98%,换手率6.74%,成交量30.85万手,成交额9.63亿元。10月20日的资金流向数据方面,主力资金净流入3999.56万元,占总成交额4.15%,游资资金净流出3754.31万元,占总成交额3.9%,散户资金净流出245.25万元,占总成交额0.25%。金域医学主营业务:为全国超过23000家各类医疗机构提供包括质谱、基因组、病理、生化发光、免疫学、其他综合等11大类共87类医学检验技术,超4000项检验项目的外包及科研技术服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100006884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882","BK0042","SG9999001069.SGD","BK0236","BK0284"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676818665","title":"金域医学涨7.98%,国金证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2676818665","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676818665?lang=zh_cn&edition=full","pubTime":"2026-10-20 16:24","pubTimestamp":1792484675,"startTime":"0","endTime":"0","summary":"今日金域医学涨7.98%,收盘报31.53元。2026年8月26日,国金证券研究员甘坛焕发布了对金域医学的研报《盈利能力修复,医数融合构筑新增长》,该研报对金域医学给出“买入”评级。研报中预计26-28年公司归母净利润为4.05/5.17/6.02亿元,分别同比增长NA、28、17%,EPS分别为0.87、1.12、1.30元,现价对应PE为34、26、23倍,维持“买入”评级。金域医学个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000024266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676682684","title":"金域医学(603882)披露持股5%以上股东权益变动触及1%刻度的提示性公告,10月19日股价上涨2.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676682684","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676682684?lang=zh_cn&edition=full","pubTime":"2026-10-19 22:33","pubTimestamp":1792420411,"startTime":"0","endTime":"0","summary":"截至2026年10月19日收盘,金域医学报收于29.2元,较前一交易日上涨2.1%,最新总市值为135.27亿元。近日,广州金域医学检验集团股份有限公司发布《关于持股5%以上股东权益变动触及1%刻度的提示性公告》。本次权益变动后,国创开元持股比例由6.67%减少至6.00%。本次减持系因基金存续期届满所致,不会导致公司控股股东及实际控制人发生变化,不涉及披露权益变动报告书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900030252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0284","603882","BK0042","BK0236","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676612510","title":"金域医学(603882)10月16日主力资金净卖出2152.66万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676612510","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676612510?lang=zh_cn&edition=full","pubTime":"2026-10-17 08:23","pubTimestamp":1792196589,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月16日收盘,金域医学报收于28.6元,下跌3.77%,换手率3.73%,成交量17.09万手,成交额5.02亿元。10月16日的资金流向数据方面,主力资金净流出2152.66万元,占总成交额4.29%,游资资金净流入4369.97万元,占总成交额8.7%,散户资金净流出2217.31万元,占总成交额4.41%。金域医学主营业务:为全国超过23000家各类医疗机构提供包括质谱、基因组、病理、生化发光、免疫学、其他综合等11大类共87类医学检验技术,超4000项检验项目的外包及科研技术服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101700005803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882","BK0042","BK0236","SG9999001069.SGD","BK0284"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675559317","title":"金域医学(603882)10月15日主力资金净买入1396.44万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675559317","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675559317?lang=zh_cn&edition=full","pubTime":"2026-10-16 08:13","pubTimestamp":1792109583,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月15日收盘,金域医学报收于29.72元,上涨2.34%,换手率3.27%,成交量15.0万手,成交额4.44亿元。融券方面,融券卖出4500.0股,融券偿还300.0股,融券余量2.0万股,融券余额59.44万元。金域医学主营业务:为全国超过23000家各类医疗机构提供包括质谱、基因组、病理、生化发光、免疫学、其他综合等11大类共87类医学检验技术,超4000项检验项目的外包及科研技术服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600007081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882","BK0042","SG9999001069.SGD","BK0236","BK0284"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675698463","title":"股市必读:金域医学新发布《广州金域医学检验集团股份有限公司关于终止对外投资的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675698463","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675698463?lang=zh_cn&edition=full","pubTime":"2026-10-14 01:16","pubTimestamp":1791911769,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总:10月13日主力资金净流出1386.1万元,占总成交额4.6%; 公司公告汇总:金域医学终止2018年发起的对香港DRA公司1.5亿元投资,该公司已于2026年10月9日被香港注册处撤销注册并解散。公司公告汇总广州金域医学检验集团股份有限公司关于终止对外投资的公告广州金域医学检验集团股份有限公司于2018年1月审议通过认购香港DRA COMPANY LIMITED新发行股份,计划投资1.5亿元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400001395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0284","SG9999001069.SGD","BK0236","BK0042","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674805785","title":"金域医学(603882)披露关于终止对外投资的公告,10月12日股价上涨2.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674805785","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674805785?lang=zh_cn&edition=full","pubTime":"2026-10-12 22:53","pubTimestamp":1791816790,"startTime":"0","endTime":"0","summary":"截至2026年10月12日收盘,金域医学报收于29.4元,较前一交易日上涨2.01%,最新总市值为136.2亿元。近日,广州金域医学检验集团股份有限公司发布《关于终止对外投资的公告》。公告显示,公司于2018年1月审议通过认购香港DRA COMPANY LIMITED新发行股份,计划投资1.5亿元人民币。2026年10月9日,DRA公司注册被香港注册处撤销并解散。本次终止对外投资不会对公司生产经营及财务状况产生重大不利影响,不存在损害公司及股东利益的情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200035767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882","BK0284","BK0236","SG9999001069.SGD","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673014065","title":"股市必读:金域医学新发布《广州金域医学检验集团股份有限公司关于股份回购实施结果暨股份变动的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673014065","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673014065?lang=zh_cn&edition=full","pubTime":"2026-10-08 01:41","pubTimestamp":1791394869,"startTime":"0","endTime":"0","summary":"公司公告汇总:金域医学完成股份回购,实际回购756.20万股、金额19,997.45万元,其中210万股已用于2026年限制性股票与股票期权激励计划首次授予。公司公告汇总广州金域医学检验集团股份有限公司关于股份回购实施结果暨股份变动的公告广州金域医学检验集团股份有限公司于2026年4月10日至10月9日期间,通过集中竞价交易方式实施股份回购,实际回购股份756.20万股,占公司总股本的1.63%,实际回购金额19,997.45万元,回购价格区间为23.36元/股至30.59元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800000955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882","BK0284","BK0236","BK0042","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671788693","title":"金域医学(603882)披露股份回购实施结果暨股份变动公告,9月30日股价上涨2.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671788693","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671788693?lang=zh_cn&edition=full","pubTime":"2026-09-30 22:15","pubTimestamp":1790777721,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘,金域医学报收于29.06元,较前一交易日上涨2.87%,最新总市值为134.62亿元。该股当日开盘28.2元,最高29.8元,最低27.88元,成交额达3.5亿元,换手率为2.63%。近日,广州金域医学检验集团股份有限公司披露《关于股份回购实施结果暨股份变动的公告》。回购完成后公司股份总数未发生变化,不影响股权分布及控制权稳定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000037953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0284","BK0042","603882","BK0236","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670401312","title":"股市必读:金域医学(603882)9月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2670401312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670401312?lang=zh_cn&edition=full","pubTime":"2026-09-28 02:56","pubTimestamp":1790535371,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘,金域医学报收于29.39元,上涨1.1%,换手率3.04%,成交量13.94万手,成交额4.13亿元。董秘最新回复投资者: 对比医学检验赛道行业同业来看,去年公司人员规模、人均营收均下降约8%。投资者: 董秘您好,半年报公布感染探针捕获、肿瘤多基因检测、全外显子检测等营收增长分别达32.5%、21.1%、19.7%。当日关注点交易信息汇总:9月24日主力资金净流入238.05万元,占总成交额0.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","BK0042","SG9999001069.SGD","BK0284","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669612874","title":"金域医学:感染探针捕获、肿瘤多基因检测、全外显子检测等同比分别实现10%~40%增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2669612874","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669612874?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:18","pubTimestamp":1790245088,"startTime":"0","endTime":"0","summary":"投资者提问:董秘您好,半年报公布感染探针捕获、肿瘤多基因检测、全外显子检测等营收增长分别达32.5%、21.1%、19.7%。2026年上半年,公司实体肿瘤、神经免疫性疾病、血液疾病、感染性疾病等检测业务实现稳健发展。其中,感染探针捕获、肿瘤多基因检测、全外显子检测等同比分别实现10%~40%增长,高于其他常规产品,成为新的业务增长极。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400032080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","BK0042","SG9999001069.SGD","BK0284","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669461253","title":"金域医学:2026年半年度实验室综合人效同比提升15.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669461253","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669461253?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:15","pubTimestamp":1790244912,"startTime":"0","endTime":"0","summary":"公司积极通过降本增效及数智化转型,强化内部运营管理,深入推进精益运营,提升运营效率。随着各项经营改善措施持续落地,公司主营业务经营保持韧性,核心业务发展逐步企稳,经营效率进一步提升,2026年第二季度,公司营业收入同比增长0.19%,2026年半年度,公司实验室综合人效同比提升15.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400032021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882","BK0236","SG9999001069.SGD","BK0284","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667365920","title":"金域医学涨6.06%,国金证券二周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667365920","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667365920?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:35","pubTimestamp":1789374958,"startTime":"0","endTime":"0","summary":"今日金域医学涨6.06%,收盘报27.48元。2026年8月26日,国金证券研究员甘坛焕发布了对金域医学的研报《盈利能力修复,医数融合构筑新增长》,该研报对金域医学给出“买入”评级。研报中预计26-28年公司归母净利润为4.05/5.17/6.02亿元,分别同比增长NA、28、17%,EPS分别为0.87、1.12、1.30元,现价对应PE为34、26、23倍,维持“买入”评级。金域医学个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400021100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507179","title":"每周股票复盘:金域医学(603882)将召开2026年半年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507179","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507179?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:21","pubTimestamp":1789237271,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘,金域医学报收于25.91元,较上周的26.7元下跌2.96%。本周,金域医学9月7日盘中最高价报26.86元。金域医学当前最新总市值120.03亿元,在医疗服务板块市值排名17/51,在两市A股市值排名1532/5218。本周关注点公司公告汇总:金域医学将于2026年9月15日召开2026年半年度业绩说明会。公司公告汇总广州金域医学检验集团股份有限公司将于2026年9月15日15:30-17:00通过“全景路演”网站召开2026年半年度业绩说明会,以网络文字互动方式与投资者交流。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","BK0042","603882","BK0284","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666515590","title":"金域医学获得发明专利授权:“基因突变分析、查询序列建立方法、系统、设备及介质”","url":"https://stock-news.laohu8.com/highlight/detail?id=2666515590","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666515590?lang=zh_cn&edition=full","pubTime":"2026-09-11 03:52","pubTimestamp":1789069958,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示金域医学新获得一项发明专利授权,专利名为“基因突变分析、查询序列建立方法、系统、设备及介质”,专利申请号为CN202510684521.1,授权日为2026年9月8日。本发明能够减少测序的操作不当或样本污染影响查询序列的准确性。今年以来金域医学新获得专利授权9个,较去年同期增加了200%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100011109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","603882","BK0236","BK0284","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666811925","title":"金域医学(603882)披露将召开2026年半年度业绩说明会,9月9日股价上涨0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666811925","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666811925?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:41","pubTimestamp":1788946897,"startTime":"0","endTime":"0","summary":"截至2026年9月9日收盘,金域医学报收于26.64元,较前一交易日上涨0.49%,最新总市值为123.41亿元。该股当日开盘26.4元,最高26.86元,最低26.26元,成交额达1.4亿元,换手率为1.14%。广州金域医学检验集团股份有限公司于近日发布《关于参加2026广东上市公司投资者集体接待日暨召开2026年半年度业绩说明会的公告》。公告显示,公司将于2026年9月15日15:30-17:00通过“全景路演”网站召开2026年半年度业绩说明会,以网络文字互动方式与投资者交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900030302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0284","603882","BK0042","BK0236","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665944310","title":"金域医学新注册《区域检验质控系统V1.0》等2个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2665944310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665944310?lang=zh_cn&edition=full","pubTime":"2026-09-08 02:15","pubTimestamp":1788804916,"startTime":"0","endTime":"0","summary":"证券之星消息,近日金域医学(603882)新注册了2个项目的软件著作权,包括《区域检验质控系统V1.0》、《金域区域检验数据平台移动端V1.0.0》等。今年以来金域医学新注册软件著作权40个,较去年同期减少了42.86%。结合公司2026年中报财务数据,今年上半年公司在研发方面投入了1.57亿元,同比减2.3%。通过天眼查大数据分析,广州金域医学检验集团股份有限公司共对外投资了59家企业,参与招投标项目30次;财产线索方面有商标信息767条,专利信息226条,著作权信息199条;此外企业还拥有行政许可62个。数据来源:天眼查APP以上内容为证券之星据公开信息整理,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800000682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","159180","BK0042","SG9999001069.SGD","BK0284","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665652983","title":"每周股票复盘:金域医学(603882)股东拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2665652983","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665652983?lang=zh_cn&edition=full","pubTime":"2026-09-06 02:25","pubTimestamp":1788632711,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘,金域医学报收于26.7元,较上周的27.42元下跌2.63%。因基金存续期届满,国创开元拟通过集中竞价方式减持不超过4,632,582股,占公司总股本的1.00%。截至2026年8月31日,已累计回购713.38万股,占总股本1.54%,支付金额18,811.76万元,回购最高价30.59元/股,最低价23.36元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","603882","BK0284","BK0236","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665565403","title":"金域医学新注册《金域学术资源运营看板系统APPV1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2665565403","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665565403?lang=zh_cn&edition=full","pubTime":"2026-09-05 02:20","pubTimestamp":1788546026,"startTime":"0","endTime":"0","summary":"证券之星消息,近日金域医学(603882)新注册了《金域学术资源运营看板系统APPV1.0》项目的软件著作权。今年以来金域医学新注册软件著作权38个,较去年同期减少了45.71%。结合公司2026年中报财务数据,今年上半年公司在研发方面投入了1.57亿元,同比减2.3%。通过天眼查大数据分析,广州金域医学检验集团股份有限公司共对外投资了59家企业,参与招投标项目30次;财产线索方面有商标信息767条,专利信息226条,著作权信息199条;此外企业还拥有行政许可62个。数据来源:天眼查APP以上内容为证券之星据公开信息整理,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090500000216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0042","BK0284","603882","159180","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664453748","title":"股市必读:金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664453748","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664453748?lang=zh_cn&edition=full","pubTime":"2026-09-03 01:53","pubTimestamp":1788371592,"startTime":"0","endTime":"0","summary":"公司公告汇总广州金域医学检验集团股份有限公司股东国创开元股权投资基金减持股份计划公告广州金域医学检验集团股份有限公司股东国创开元股权投资基金持有公司30,880,905股,占总股本的6.67%,股份来源为公司首次公开发行前取得。因基金存续期届满,国创开元拟通过集中竞价方式减持不超过4,632,582股,占公司总股本的1.00%。截至2026年8月31日,已累计回购713.38万股,占总股本1.54%,支付金额18,811.76万元,回购最高价30.59元/股,最低价23.36元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","SG9999001069.SGD","BK0284","603882","BK0042"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792793010611,"stockEarnings":[{"period":"1week","weight":0.0699},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.1783},{"period":"6month","weight":0.082},{"period":"1year","weight":0.1074},{"period":"ytd","weight":0.1093}],"compareEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":-0.0625},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.0954},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广州金域医学检验集团股份有限公司","boardCode":"AI0083","boardName":"卫生","stockholders":"39725人(较上一季度减少7.89%)","perCapita":"11530股","listingDate":"2017-09-08","address":"广东省广州市海珠区国际生物岛螺旋三路10号","registeredCapital":"46325万元","survey":" 广州金域医学检验集团股份有限公司的主营业务是第三方医学检验及病理诊断业务。公司的主要产品是医学诊断服务、销售诊断产品、健康体检业务、冷链物流服务。公司成功入选国家工业和信息化部公布的第七批产业技术基础公共服务平台名单,成为本次获批单位中唯一一家第三方医检机构,标志着公司的综合实力获得国家权威认可。","listedPrice":6.93},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金域医学(603882)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金域医学(603882)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金域医学,603882,金域医学股票,金域医学股票老虎,金域医学股票老虎国际,金域医学行情,金域医学股票行情,金域医学股价,金域医学股市,金域医学股票价格,金域医学股票交易,金域医学股票购买,金域医学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金域医学(603882)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金域医学(603882)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}